Site-specific effects of cerivastatin on bone in male Sprague-Dawley rats

Jameela Banu, Dike N. Kalu

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

It is well established that age-related bone loss occurs in men and male SD rats. This study was designed to determine whether cerivastatin will prevent age-related bone loss in male Sprague-Dawley (SD) rats. Parathyroid hormone (PTH) was used as a positive control. Nine-month-old male SD rats were divided into six groups. Group 1: baseline controls; group 2: age-matched controls; group 3: low-dose cerivastatin (0.2 mg/kg b wt/day); group 4: medium-dose cerivastatin (0.4 mg/kg b wt/day); group 5: high-dose cerivastatin (0.8 mg/kg b wt/day); group 6: PTH (80 μg/kg b wt, 5 days/week). The animals were treated for 6 months. Cancellous and cortical bones were analyzed using peripheral quantitative computerized tomography (pQCT) densitometry at the proximal tibial metaphysis (PTM), tibial diaphysis, tibio-fibula junction, femoral diaphysis and the neck of the femur. In the PTM, pQCT analyses were done 2 mm distal from the growth plate. The cancellous bone mineral content (Cn. BMC) decreased by 26% (P < 0.05), 25% (P < 0.05) and 28% (P < 0.05) in the low, medium and high doses of cerivastatin groups, respectively, when compared to the age-matched controls. PTH group did not change significantly from the baseline controls but prevented the decrease in Cn. BMC seen in the age-matched controls by 45% (P < 0.0001). Cancellous bone mineral density (Cn. BMD) decreased by 20% (P < 0.05), 23% (P < 0.05) and 27% (P < 0.05) in the low, medium and high doses of cerivastatin groups, respectively, when compared to the age-matched controls. Cn. BMD did not change significantly in the PTH-treated group when compared to the baseline controls but prevented the decrease seen in age-matched controls by 47% (P < 0.0001). In the neck of the femur, femoral diaphysis, tibial diaphysis and the tibio-fibula junction, cerivastatin did not prevent age-related bone loss in male SD rats while PTH significantly prevented the age-related bone loss. We conclude that cerivastatin, in any of the doses tested, does not prevent age-related bone loss, in male SD rats, at the different bone sites studied; while PTH not only prevented age-related bone loss but also increased bone mass above the baseline controls in all the bone sites studied except the PTM.

Original languageEnglish (US)
Pages (from-to)432-442
Number of pages11
JournalBone
Volume34
Issue number3
DOIs
StatePublished - Mar 2004

Fingerprint

Sprague Dawley Rats
Parathyroid Hormone
Osteoporosis
Bone and Bones
Diaphyses
Bone Density
Femur Neck
Fibula
Tomography
Growth Plate
cerivastatin
Densitometry
Femur
Age Groups
Cancellous Bone

Keywords

  • Bone loss
  • Cerivastatin
  • SD rats

ASJC Scopus subject areas

  • Physiology
  • Hematology

Cite this

Site-specific effects of cerivastatin on bone in male Sprague-Dawley rats. / Banu, Jameela; Kalu, Dike N.

In: Bone, Vol. 34, No. 3, 03.2004, p. 432-442.

Research output: Contribution to journalArticle

Banu, Jameela ; Kalu, Dike N. / Site-specific effects of cerivastatin on bone in male Sprague-Dawley rats. In: Bone. 2004 ; Vol. 34, No. 3. pp. 432-442.
@article{be021230c27344e0ac50a383bfdbbb77,
title = "Site-specific effects of cerivastatin on bone in male Sprague-Dawley rats",
abstract = "It is well established that age-related bone loss occurs in men and male SD rats. This study was designed to determine whether cerivastatin will prevent age-related bone loss in male Sprague-Dawley (SD) rats. Parathyroid hormone (PTH) was used as a positive control. Nine-month-old male SD rats were divided into six groups. Group 1: baseline controls; group 2: age-matched controls; group 3: low-dose cerivastatin (0.2 mg/kg b wt/day); group 4: medium-dose cerivastatin (0.4 mg/kg b wt/day); group 5: high-dose cerivastatin (0.8 mg/kg b wt/day); group 6: PTH (80 μg/kg b wt, 5 days/week). The animals were treated for 6 months. Cancellous and cortical bones were analyzed using peripheral quantitative computerized tomography (pQCT) densitometry at the proximal tibial metaphysis (PTM), tibial diaphysis, tibio-fibula junction, femoral diaphysis and the neck of the femur. In the PTM, pQCT analyses were done 2 mm distal from the growth plate. The cancellous bone mineral content (Cn. BMC) decreased by 26{\%} (P < 0.05), 25{\%} (P < 0.05) and 28{\%} (P < 0.05) in the low, medium and high doses of cerivastatin groups, respectively, when compared to the age-matched controls. PTH group did not change significantly from the baseline controls but prevented the decrease in Cn. BMC seen in the age-matched controls by 45{\%} (P < 0.0001). Cancellous bone mineral density (Cn. BMD) decreased by 20{\%} (P < 0.05), 23{\%} (P < 0.05) and 27{\%} (P < 0.05) in the low, medium and high doses of cerivastatin groups, respectively, when compared to the age-matched controls. Cn. BMD did not change significantly in the PTH-treated group when compared to the baseline controls but prevented the decrease seen in age-matched controls by 47{\%} (P < 0.0001). In the neck of the femur, femoral diaphysis, tibial diaphysis and the tibio-fibula junction, cerivastatin did not prevent age-related bone loss in male SD rats while PTH significantly prevented the age-related bone loss. We conclude that cerivastatin, in any of the doses tested, does not prevent age-related bone loss, in male SD rats, at the different bone sites studied; while PTH not only prevented age-related bone loss but also increased bone mass above the baseline controls in all the bone sites studied except the PTM.",
keywords = "Bone loss, Cerivastatin, SD rats",
author = "Jameela Banu and Kalu, {Dike N.}",
year = "2004",
month = "3",
doi = "10.1016/j.bone.2003.10.008",
language = "English (US)",
volume = "34",
pages = "432--442",
journal = "Bone",
issn = "8756-3282",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Site-specific effects of cerivastatin on bone in male Sprague-Dawley rats

AU - Banu, Jameela

AU - Kalu, Dike N.

PY - 2004/3

Y1 - 2004/3

N2 - It is well established that age-related bone loss occurs in men and male SD rats. This study was designed to determine whether cerivastatin will prevent age-related bone loss in male Sprague-Dawley (SD) rats. Parathyroid hormone (PTH) was used as a positive control. Nine-month-old male SD rats were divided into six groups. Group 1: baseline controls; group 2: age-matched controls; group 3: low-dose cerivastatin (0.2 mg/kg b wt/day); group 4: medium-dose cerivastatin (0.4 mg/kg b wt/day); group 5: high-dose cerivastatin (0.8 mg/kg b wt/day); group 6: PTH (80 μg/kg b wt, 5 days/week). The animals were treated for 6 months. Cancellous and cortical bones were analyzed using peripheral quantitative computerized tomography (pQCT) densitometry at the proximal tibial metaphysis (PTM), tibial diaphysis, tibio-fibula junction, femoral diaphysis and the neck of the femur. In the PTM, pQCT analyses were done 2 mm distal from the growth plate. The cancellous bone mineral content (Cn. BMC) decreased by 26% (P < 0.05), 25% (P < 0.05) and 28% (P < 0.05) in the low, medium and high doses of cerivastatin groups, respectively, when compared to the age-matched controls. PTH group did not change significantly from the baseline controls but prevented the decrease in Cn. BMC seen in the age-matched controls by 45% (P < 0.0001). Cancellous bone mineral density (Cn. BMD) decreased by 20% (P < 0.05), 23% (P < 0.05) and 27% (P < 0.05) in the low, medium and high doses of cerivastatin groups, respectively, when compared to the age-matched controls. Cn. BMD did not change significantly in the PTH-treated group when compared to the baseline controls but prevented the decrease seen in age-matched controls by 47% (P < 0.0001). In the neck of the femur, femoral diaphysis, tibial diaphysis and the tibio-fibula junction, cerivastatin did not prevent age-related bone loss in male SD rats while PTH significantly prevented the age-related bone loss. We conclude that cerivastatin, in any of the doses tested, does not prevent age-related bone loss, in male SD rats, at the different bone sites studied; while PTH not only prevented age-related bone loss but also increased bone mass above the baseline controls in all the bone sites studied except the PTM.

AB - It is well established that age-related bone loss occurs in men and male SD rats. This study was designed to determine whether cerivastatin will prevent age-related bone loss in male Sprague-Dawley (SD) rats. Parathyroid hormone (PTH) was used as a positive control. Nine-month-old male SD rats were divided into six groups. Group 1: baseline controls; group 2: age-matched controls; group 3: low-dose cerivastatin (0.2 mg/kg b wt/day); group 4: medium-dose cerivastatin (0.4 mg/kg b wt/day); group 5: high-dose cerivastatin (0.8 mg/kg b wt/day); group 6: PTH (80 μg/kg b wt, 5 days/week). The animals were treated for 6 months. Cancellous and cortical bones were analyzed using peripheral quantitative computerized tomography (pQCT) densitometry at the proximal tibial metaphysis (PTM), tibial diaphysis, tibio-fibula junction, femoral diaphysis and the neck of the femur. In the PTM, pQCT analyses were done 2 mm distal from the growth plate. The cancellous bone mineral content (Cn. BMC) decreased by 26% (P < 0.05), 25% (P < 0.05) and 28% (P < 0.05) in the low, medium and high doses of cerivastatin groups, respectively, when compared to the age-matched controls. PTH group did not change significantly from the baseline controls but prevented the decrease in Cn. BMC seen in the age-matched controls by 45% (P < 0.0001). Cancellous bone mineral density (Cn. BMD) decreased by 20% (P < 0.05), 23% (P < 0.05) and 27% (P < 0.05) in the low, medium and high doses of cerivastatin groups, respectively, when compared to the age-matched controls. Cn. BMD did not change significantly in the PTH-treated group when compared to the baseline controls but prevented the decrease seen in age-matched controls by 47% (P < 0.0001). In the neck of the femur, femoral diaphysis, tibial diaphysis and the tibio-fibula junction, cerivastatin did not prevent age-related bone loss in male SD rats while PTH significantly prevented the age-related bone loss. We conclude that cerivastatin, in any of the doses tested, does not prevent age-related bone loss, in male SD rats, at the different bone sites studied; while PTH not only prevented age-related bone loss but also increased bone mass above the baseline controls in all the bone sites studied except the PTM.

KW - Bone loss

KW - Cerivastatin

KW - SD rats

UR - http://www.scopus.com/inward/record.url?scp=1542376114&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1542376114&partnerID=8YFLogxK

U2 - 10.1016/j.bone.2003.10.008

DO - 10.1016/j.bone.2003.10.008

M3 - Article

C2 - 15003791

AN - SCOPUS:1542376114

VL - 34

SP - 432

EP - 442

JO - Bone

JF - Bone

SN - 8756-3282

IS - 3

ER -